Quantcast

Latest Jeff Kindler Stories

2011-01-10 07:30:00

SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the appointment of Dr. Hank McKinnell to its Board of Directors. Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc. He is currently Chairman of the Accordia Global Health Foundation, an organization dedicated to fighting infectious diseases in Africa, and is a member of the boards of Moody's Corporation, Angiotech...

2010-12-05 19:09:00

NEW YORK, Dec. 5, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected Ian C. Read, 57, currently head of the Company's global biopharmaceutical operations, as President, Chief Executive Officer and Director. Mr. Read succeeds Jeffrey B. Kindler, who has retired from the Company. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) The Board's Lead Independent Director, Constance J. Horner, said, "In 2006, Jeff...

2010-11-02 06:00:00

NEW YORK, Nov. 2, 2010 /PRNewswire-FirstCall/ -- Third-Quarter 2010 Revenues of $16.2 Billion Third-Quarter 2010 Adjusted Diluted EPS((1)) of $0.54; Reported Diluted EPS((2)) of $0.11 Tightens Ranges for 2010 Financial Guidance Components, Increases Range for Adjusted Diluted EPS((1)) and Reduces Range for Reported Diluted EPS((2)); Reaffirms 2012 Financial Targets Advances Strategic Priorities with Agreement to Acquire King Pharmaceuticals, Inc., Acquisition of FoldRx, Alliance with...

2010-05-04 06:00:00

NEW YORK May 4 /PRNewswire-FirstCall/ -- First-Quarter 2010 Revenues of $16.8 Billion First-Quarter 2010 Reported Diluted EPS(1) of $0.25, Adjusted Diluted EPS(2) of $0.60 Reaffirms 2010 Financial Guidance and 2012 Diluted EPS Target Ranges Continues to Make Solid Progress on the Wyeth Integration ($ in millions, except per share amounts) First-Quarter ------------- 2010...

5925904850fbb391d059adec16e388761
2009-01-26 13:35:00

Pfizer has entered into a deal worth $68 billion to buy rival drug maker Wyeth, the two companies announced. The U.S. drug maker Pfizer will now be able to protect itself from a revenue drop once its popular drug Lipitor and other products lose patent protection. The company will also be able to diversify its product portfolio due to Wyeth's presence in biotech drugs and vaccines. Pfizer is also expected to cut 10 percent of its global workforce, or 8,000 jobs, and shut some manufacturing...

2009-01-26 00:31:49

The board of Pfizer Inc. has agreed to terms of a deal to take over Wyeth for $68 billion, The New York Times reported Monday. Pfizer, the largest pharmaceutical company in the world, would acquire Wyeth for a combination of $26 billion in cash as well as loans and stock, the newspaper said, citing people involved in the negotiations. The report said five banks have agreed to lend Pfizer $22.5 billion to finance the deal, making it the first major merger in months that has drawn the support...

2008-07-24 12:00:00

Pfizer has posted a net income of $2.8 billion in the second quarter of 2008, an increase of 119% compared with $1.3 billion in the corresponding period of 2007. The company reported diluted EPS of $0.41 in the second quarter of 2008, an increase of 128% compared with $0.18 in the prior-year quarter. Total revenues for the quarter were $12.1 billion, an increase of 9% compared with $11.1 billion for the same quarter in 2007. Pharmaceutical revenues for the quarter were $11.1 billion, an...

2007-08-22 09:13:29

Pfizer today announced that Frank A. D'Amelio, a senior executive with almost three decades of extensive operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as both chief operating officer and chief financial officer at Lucent, will become Pfizer's Senior Vice President and Chief Financial Officer effective in mid-September. Mr. D'Amelio, who is currently Senior Executive Vice President, Integration and Chief Administrative Officer...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related